共 50 条
- [31] Phase III randomized, controlled trial of pre-emptive vs. standard prophylaxis to prevent inhibitor formation in children with severe hemophilia A: the inhibit studyHAEMOPHILIA, 2011, 17 (03) : 563 - 563Ragni, M.Kessler, C.Fogarty, P.Josephson, N.Neff, A.Raffini, L.
- [32] A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: Comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimensTHROMBOSIS RESEARCH, 2014, 134 (06) : 1253 - 1264Providencia, RuiGrove, Erik LerkevangHusted, SteenBarra, SergioBoveda, SergeMorais, Joao
- [33] A Phase III Randomized Study of High-dose Conventional vs. Hypofractionated Radiotherapy in Patients with High-risk Prostate CancerINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S79 - S80Arcangeli, G.Saracino, B.Gomellini, S.Petrongari, M.Arcangeli, S.Sentinelli, S.Strigari, L.
- [34] Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)FRONTIERS IN ONCOLOGY, 2023, 13Meertens, MarindaMuntinghe-Wagenaar, M. BentheSikkema, Barend J.Lopez-Yurda, MartaRetel, Valesca P.Paats, Marthe S.Ter Heine, RobSchuuring, EdTimens, WimTouw, Daan J.van Boven, Job F. M.de Langen, Adrianus. J.Hashemi, Sayed M. S.Hendriks, Lizza E. L.Croes, Sandervan den Heuvel, Michel M.Dingemans, Anne-Marie C.Mathijssen, Ron H. J.Smit, Egbert F.Huitema, Alwin D. R.Steeghs, Neeltjevan der Wekken, Anthonie J.
- [35] Randomized phase III trials of Myocet (liposome-encapsulated doxorubicin) vs. doxorubicin or epirubicin in first-line treatment of metastatic breast cancer.ANNALS OF ONCOLOGY, 2000, 11 : 26 - 26Batist, GWiner, EChan, SJain, DLee, LAzarnia, N
- [36] Effects of denosumab versus zoledronic acid (ZA) on health-elated quality of life (HRQL) in metastatic breast cancer: Results from a randomized phase III trial.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Fallowfield, L.Patrick, D.Body, J.Lipton, A.Tonkin, K. S.Qian, Y.Jiang, Q.Dansey, R. D.Chung, K.
- [37] Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)ANNALS OF ONCOLOGY, 2015, 26 (10) : 2097 - 2101Ryu, M. -H.Baba, E.Lee, K. H.Park, Y. I.Boku, N.Hyodo, I.Nam, B. -H.Esaki, T.Yoo, C.Ryoo, B. -Y.Song, E. -K.Cho, S. -H.Kang, W. K.Yang, S. H.Zang, D. Y.Shin, D. B.Park, S. R.Shinozaki, K.Takano, T.Kang, Y. -K.
- [38] Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study groupJOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3150 - 3157Rosen, LSGordon, DTchekmedyian, SYanagihara, RHirsh, VKrzakowski, MPawlicki, Mde Souza, PZheng, MUrbanowitz, GReitsma, DSeaman, JJ
- [39] A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard ChemotherapyJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (11) : 1197 - +Leyland-Jones, BrianBondarenko, IgorNemsadze, GiaSmirnov, VitaliyLitvin, IrynaKokhreidze, IrakliAbshilava, LiaJanjalia, MikheilLi, RubiLakshmaiah, Kuntegowda C.Samkharadze, BekaTarasova, OksanaMohapatra, Ranjan KumarSparyk, YaroslavPolenkov, SergeyVladimirov, VladimirXiu, LiangZhu, EugeneKimelblatt, BruceDeprince, KrisSafonov, IlyaBowers, PeterVercammen, Els
- [40] Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast cancer (MBC)ANNALS OF ONCOLOGY, 1998, 9 : 12 - 12Winer, EBatist, GHarris, LHooftman, LPark, Y